Skip to content
Log in
Sponsored AI AM CLAUDE, A Beginner's Guide: Learn the basics of working with AI AI AM CLAUDE, A Beginner's Guide: Learn the basics of working with AI
Review

Anti-PD-1 single-chain variable fragments in cancer immunotherapy: from molecular engineering to clinical translation

Zahraa A. Alkhafaje H. Malathi A. Dash J. P. Selvakumari Gurjant Singh Aashna Sinha Muath Suliman A. Smerat
Jul 2026 · Cancer Chemotherapy and Pharmacology · Vol 96 · 0 citations · 109 references
Medicine

TL;DR

Taken together, anti-PD-1 scFvs represent a modular platform for localized checkpoint inhibition and potentially improved cost-effectiveness compared with systemic antibodies.

DOI PubMed Semantic Scholar
View source

Similar papers

Review Open access Sep 2026

Structural Foundation of CTLA-4 antibodies: Emerging Platforms for Next-generation Cancer Immunotherapy.

By connecting atomic-level receptor recognition to clinical outcome, this review provides a mechanistic foundation for the rational design of next-generation CTLA-4 therapeutics with improved efficacy and reduced immune-related toxicity.

Enat Mengistu Leta, S. Syed, Geleta Negasa Binegde et al. · 0 citations
Review Open access Sep 2026

Effector-cell-engaging bispecific antibodies for cancer therapeutics: engineering precision immunity.

This review outlines the evolution of effector-cell-engaging bsAb formats, such as BiTEs, DARTs, TandAbs and IgG-like constructs, along with engineering strategies to enhance Fc function, valency, half-life, safety and efficacy.

A. Gholap, P. Khuspe, Darshana Morankar et al. · 0 citations
Open access Aug 2026

Overcoming immune checkpoint inhibitor-mediated T-cell exhaustion with a TCR β chain-directed selective dual T-cell activator

Administration of anti-PD-1 with a bifunctional fusion molecule, anti-TCRβ-IL-2 followed by anti-PD-1 greatly enhanced anti-tumor efficacy leading to tumor cures and long-term protection in several murine models resistant to ICI.

Shantel Angstadt, Lucas A. Horn, Kristen Fousek et al. · 0 citations
Open access Aug 2026

Bispecific Antibodies Targeting PD-1/PD-L1 and VEGF in Non-Small Cell Lung Cancer

Mature randomized survival data, longer-term safety assessment, and biomarker development are needed to define optimal patient selection and the clinical role of PD-(L)1/VEGF bispecific antibodies in NSCLC.

Aleena Kuriakose, Salem Gogah, E. Beleva · 0 citations
Jul 2026

Discovery and development of small-molecule inhibitors targeting cytotoxic T lymphocyte associated protein 4 to enhance cancer immunotherapy and reduce side effects.

D11 and A9 compounds were found to be effective at inhibiting tumor growth and prolonging survival in mouse models expressing humanised CTLA-4, highlighting their ability to overcome the limitations of anti-CTLA-4 antibodies.

Chong Yu, Xiaohua Zhou, Wenqiang Chen et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.